“We know that of the one in six couples who will experience difficulties getting pregnant, a significant portion of them will not be able to afford the treatments that could help them conceive,” said Richard Paulson, MD, director of USC Fertility and senior author of the study. Paulson is one of the preeminent fertility physicians in the world to use modified natural cycle IVF. “Modified natural cycle lowers the barrier of entry for these couples and affords them the opportunity to grow their families.”
The study analyzed six IVF treatment strategies against six similar modified natural cycle IVF strategies for infertile patients under 35 years of age with good prognosis. Some of these strategies included a frozen embryo transfer, though the likelihood of an embryo being available using IVF was 90 percent, as opposed to 30 percent after modified natural cycle IVF. The costs were then assessed against the number of live births that resulted from each plan to create a cost-effectiveness ratio.
The cost savings of modified natural cycle IVF were significant. One round of modified natural cycle IVF represented a cost savings of more than $7,000 for each live birth over IVF. The most cost-effective strategy was two cycles of modified natural cycle with two possible frozen embryo transfers, which cost $6,500 less than a similar strategy using IVF.
Modified natural cycle IVF involves giving the prospective mother three to four days of medication to block spontaneous ovulation, as well as low-dose hormones. This method takes less time than conventional IVF, which can take up to four to six weeks for one cycle. Moreover, modified natural cycle is gentler on the body, which lowers the chance of complications over the course of treatment. Because it is a less aggressive method, it is most effective in women under the age of 35.
“Young couples experiencing fertility issues may have fewer financial resources and lower access to care, but can still achieve great success with modified natural cycle IVF,” said Wael Salem, MD, a postdoctoral fellow at Keck Medicine of USC and first author of the study. “Our hope is that with this research, fertility centers will price this treatment even more competitively, providing a service to younger patients while maintaining positive outcomes.”
# # #
ABOUT KECK MEDICINE OF USCKeck Medicine of USC is the University of Southern California's medical enterprise, one of only two university-based medical systems in the Los Angeles area. Encompassing academic, research and clinical excellence, the medical system attracts internationally renowned physicians and scientists who serve as faculty at the Keck School of Medicine of USC and practice through the USC Care Medical Group. The Keck Medical Center of USC includes two acute care hospitals: 401-licensed bed Keck Hospital of USC and 60-licensed bed USC Norris Cancer Hospital, one of the first comprehensive cancer centers established by the National Institutes of Health (NIH) in the United States. The medical system also includes USC Verdugo Hills Hospital, a 158-licensed bed community hospital, and more than 40 outpatient facilities, some at affiliated hospitals, in Los Angeles, Orange, Kern, Tulare, and Ventura counties.
In 2016, U.S. News & World Report ranked Keck Medical Center of USC among the Top 20 hospitals in the United States in ophthalmology, urology and cancer care, and among the Top 50 hospitals for geriatric care, orthopaedic care, nephrology and cardiology.
For more information, go to www.keckmedicine.org/beyond
RSS